Clovis Oncology Inc

CLVS:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/15/21 EST
5.60quote price arrow up+0.02 (+0.36%)
Volume
79,256
Close
5.58quote price arrow down-0.38 (-6.38%)
Volume
5,157,731
52 week range
3.62 - 11.63

...

Loading . . .

KEY STATS

  • Open5.96
  • Day High5.98
  • Day Low5.57
  • Prev Close5.96
  • 52 Week High11.63
  • 52 Week High Date02/20/20
  • 52 Week Low3.62
  • 52 Week Low Date03/17/20
  • Market Cap492.83M
  • Shares Out88.32M
  • 10 Day Average Volume5.10M
  • Dividend-
  • Dividend Yield-
  • Beta1.89
  • 1 Year % Change-41.11

RATIOS/PROFITABILITY

  • EPS (TTM)-5.24
  • P/E (TTM)-1.07
  • Fwd P/E (NTM)-1.99
  • EBITDA (MRQ)-320.68M
  • ROE (MRQ)-547.55%
  • Revenue (MRQ)160.53M
  • Gross Margin (MRQ)75.31%
  • Net Margin (MRQ)-230.33%
  • Debt To Equity (MRQ)-365.67%

EVENTS

  • Earnings Date02/23/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Clovis Oncology Inc News

There is no recent news for this security.

Latest CLVS News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company...
Ginger Graham
Chairman
Patrick Mahaffy
President
Daniel Muehl CPA
Chief Financial Officer
Ann Bozeman
Executive Vice President
Paul Gross J.D.
Executive Vice President
Address
5500 Flatiron Pkwy Unit 100
Boulder, CO
80301-2834
United States